Radiation therapy combined with hormone therapy for prostate cancer

Seminars in Radiation Oncology

Volumn 16, Issue 1, 2006, Pages 20-28

  Lee, Andrew K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN THERAPY; ANEMIA; ATROPHY; BONE DEFECT; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REGIMEN; FRACTURE; GLEASON SCORE; GYNECOMASTIA; HUMAN; LIVER TOXICITY; LONG TERM CARE; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW;

EID: 29244491131     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.08.003     Document Type: Article

References (42)

1. A.L. Zietman, B.M. Nakfoor, E.A. Prince The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor An in vitro and in vivo study Cancer J Sci Am 3 1997 31 36
2. T. Granfors, J.E. Damber, A. Bergh Combined castration and fractionated radiotherapy in an experimental prostatic adenocarcinoma Int J Radiat Oncol Biol Phys 39 1997 1031 1036
3. D.L. Joon, M. Hasegawa, C. Sikes Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation Int J Radiat Oncol Biol Phys 38 1997 1071 1077
4. A. Pollack, F. Ashoori, C. Sikes The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions Int J Radiat Oncol Biol Phys 46 2000 153 158
5. A. Pollack, N. Salem, F. Ashoori Lack of prostate cancer radiosensitization by androgen deprivation Int J Radiat Oncol Biol Phys 51 2001 1002 1007
6. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
7. M.V. Pilepich, K. Winter, C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290
8. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial Lancet 360 2002 103 106
9. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
10. M.V. Pilepich, J.M. Krall, M. al-Sarraf Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group Urology 45 1995 616 623
11. M.V. Pilepich, K. Winter, M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
12. G.E. Hanks, T.F. Pajak, A. Porter The Radiation Therapy Oncology Group Protocol 92-02 Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate J Clin Oncol 21 2003 3972 3978
13. rd, M. DeSilvio, C. Lawton Radiation Therapy Oncology Group 9413 Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression J Clin Oncol 21 2003 1904 1911
14. A.V. D'Amico, D. Schultz, M. Loffredo Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer JAMA 284 2000 1280 1283
15. A.V. D'Amico, J. Manola, M. Loffredo 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer A randomized controlled trial JAMA 292 2004 821 827
16. M.G. Oefelein, V. Ricchuiti, W. Conrad Skeletal fracture associated with androgen suppression induced osteoporosis The clinical incidence and risk factors for patients with prostate cancer J Urol 166 2001 1724 1728
17. H.W. Daniell Osteoporosis after orchiectomy for prostate cancer J Urol 157 1997 439 444
18. V.B. Shahinian, Y.F. Kuo, J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
19. M.R. Smith Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer Urology 63 2004 742 745
20. M.R. Smith Changes in body composition during hormonal therapy for prostate cancer Clin Prostate Cancer 2 2003 18 21
21. S.B. Strum, J.E. McDermed, M.C. Scholz Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade Br J Urol 79 1997 933 941
22. M.G. Oefelein Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting Implications for dosing schedule and neoadjuvant study consideration J Urol 160 1998 1685 1688
23. G.D. Padula, M.J. Zelefsky, E.S. Venkatraman Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 52 2002 439 443
24. T. Granfors, R. Tomic, A. Bergh After radiotherapy testosterone stimulation is unable to increase growth in the dunning R3327-PAP prostate tumour Urol Res 27 1999 357 361
25. J. Crook, C. Ludgate, S. Malone Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 60 2004 15 23
26. P. Iversen, C.J. Tyrrell, A.V. Kaisary Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer Results from two multicenter randomized trials at a median follow-up of 4 years Urology 51 1998 389 396
27. P. Iversen Quality of life issues relating to endocrine treatment options Eur Urol 36 suppl 2 1999 20 26
28. C.J. Tyrrell, A.V. Kaisary, P. Iversen A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 33 1998 447 456
29. G. Sanguineti, M. Marcenaro, P. Franzone Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy Radiother Oncol 66 2003 151 157
30. M.J. Zelefsky, A. Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer Reducing the potential morbidity of therapy Urology 49 1997 38 45
31. R. Kucway, F. Vicini, R. Huang Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy J Urol 167 2002 2443 2447
32. C. Selli, R. Montironi, A. Bono Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer J Clin Pathol 55 2002 508 513
33. M.S. Steiner Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival Curr Urol Rep 1 2000 7 8
34. M.S. Steiner Neoadjuvant androgen ablation before radical prostatectomy reduces positive margin rate, but has no effect on 36-month post-treatment biochemical failure Curr Urol Rep 2 2001 193 194
35. M.S. Soloway, K. Pareek, R. Sharifi Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer 5-year results J Urol 167 2002 112 116
36. A.K. Lee, A. Melancon, R. Cheung Under-dosing of potential microscopic prostate cancer with IMRT after neoadjuvant hormonal therapy Int J Radiat Oncol Biol Phys 60 2004 S449
37. A. Pollack, L.G. Smith, A.C. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
38. M.J. Zelefsky, Z. Fuks, M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881
39. A. Pollack, A.L. Hanlon, E.M. Horwitz Prostate cancer radiotherapy dose response An update of the fox chase experience J Urol 171 2004 1132 1136
40. A. Pollack, G.K. Zagars, L.G. Smith Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 2000 3904 3911
41. A. Pollack, G.K. Zagars, G. Starkschall Prostate cancer radiation dose response Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
42. K.H. Nguyen, E.M. Horwitz, A.L. Hanlon Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 57 2003 377 383